Price Alert

SpringWorks Therapeutics ... (SWTX)

NASDAQ: SWTX · Real-Time Price · USD

46.99

0.00 (0.00%)

At close: Jun 30, 2025, 3:59 PM

SpringWorks Therapeutics Statistics

Share Statistics

SpringWorks Therapeutics has 75.35M shares outstanding. The number of shares has increased by 1.45% in one year.

Shares Outstanding	75.35M
Shares Change (YoY)	1.45%
Shares Change (QoQ)	0.55%
Owned by Institutions (%)	98.01%
Shares Floating	72.94M
Failed to Deliver (FTD) Shares	10
FTD / Avg. Volume	n/a

Short Selling Information

The latest short interest is 6.92M, so 0% of the outstanding shares have been sold short.

Short Interest	6.92M
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	1.32

Valuation Ratios

The PE ratio is -10.38 and the forward PE ratio is -56.61. SpringWorks Therapeutics's PEG ratio is 0.32.

PE Ratio	-10.38
Forward PE	-56.61
PS Ratio	13.98
Forward PS	5.8
PB Ratio	5.57
P/FCF Ratio	-14.88
PEG Ratio	0.32

Financial Ratio History

Enterprise Valuation

Currently the Enterprise Value (EV) is not available for SpringWorks Therapeutics.

EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 3.81, with a Debt / Equity ratio of 0.02.

Current Ratio	3.81
Quick Ratio	3.7
Debt / Equity	0.02
Debt / EBITDA	-0.03
Debt / FCF	-0.04
Interest Coverage	0

Financial Efficiency

Return on Equity is n/a and Return on Invested Capital is n/a.

Return on Equity	n/a
Return on Assets	n/a
Return on Invested Capital	n/a
Revenue Per Employee	$520.62K
Profits Per Employee	$-701.44K
Employee Count	368
Asset Turnover	0.33
Inventory Turnover	1.23

Taxes

Income Tax	n/a
Effective Tax Rate	0%

Stock Price Statistics

The stock price has increased by 26.83% in the last 52 weeks. The beta is 0.7, so SpringWorks Therapeutics's price volatility has been higher than the market average.

Beta	0.7
52-Week Price Change	26.83%
50-Day Moving Average	46.26
200-Day Moving Average	41.29
Relative Strength Index (RSI)	63.71
Average Volume (20 Days)	5,845,442

Income Statement

In the last 12 months, SpringWorks Therapeutics had revenue of 191.59M and earned -258.13M in profits. Earnings per share was -3.48.

Revenue	191.59M
Gross Profit	179.04M
Operating Income	-278.13M
Net Income	-258.13M
EBITDA	-278.13M
EBIT	-278.13M
Earnings Per Share (EPS)	-3.48

Full Income Statement

Balance Sheet

The company has 69.75M in cash and 7.91M in debt, giving a net cash position of 61.84M.

Cash & Cash Equivalents	69.75M
Total Debt	7.91M
Net Cash	61.84M
Retained Earnings	-1.15B
Total Assets	505.36M
Working Capital	274.05M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -175.6M and capital expenditures -4.45M, giving a free cash flow of -180.05M.

Operating Cash Flow	-175.6M
Capital Expenditures	-4.45M
Free Cash Flow	-180.05M
FCF Per Share	-2.43

Full Cash Flow Statement

Margins

Gross margin is 93.45%, with operating and profit margins of -145.17% and -134.73%.

Gross Margin	93.45%
Operating Margin	-145.17%
Pretax Margin	-134.73%
Profit Margin	-134.73%
EBITDA Margin	-145.17%
EBIT Margin	-145.17%
FCF Margin	-93.98%

Dividends & Yields

SWTX does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Payout Ratio	n/a
Earnings Yield	n/a
FCF Yield	n/a

Dividend Details

Analyst Forecast

Currently there are no analyst rating for SWTX.

Price Target	$47
Price Target Difference	0%
Analyst Consensus	Hold
Analyst Count	7

Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value	n/a
Lynch Upside	n/a
Graham Number	n/a
Graham Upside	n/a

Scores

Altman Z-Score	20.08
Piotroski F-Score	3